H.C. Wainwright analyst Edward White lowered his price target for Chimerix to $7 from $10 following the company's Q4 results and platform updates. The company reported that due to regulatory and site initiation delays, Phase 2 AdAPT study enrollment is expected to be substantially delayed beyond the projected 2019 timeframe, which will push back top-line data from the 16-week primary endpoint that was expected in 2020, White tells investors in a research note. The analyst now project an oral brincidofovir launch in 2022 in adenovirus patients, with sales of $61M that year. He keeps a Buy rating on Chimerix.